This trial is conducted in Japan. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 (NN-X14Mix50) in healthy Japanese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
30
A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
Novo Nordisk Investigational Site
Tokyo, Japan
Area under the insulin aspart concentration-time curve in the interval from 0 to 16 hours
Cmax, maximum insulin aspart concentration
Area under the insulin aspart concentration-time curve
Tmax, time to maximum insulin aspart concentration
MRT, mean residence time
t½, terminal half-life
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.